Literature DB >> 23327817

Hepatitis in an infant treated with octreotide for congenital hyperinsulinism.

Ilana Koren1, Arieh Riskin, Winfried Barthlen, David Gillis.   

Abstract

Congenital hyperinsulinism is characterized by hypoglycemia caused by several genetic disorders of inappropriate insulin secretion. Octreotide, an analogue of somatostatin, plays a major role in the pharmaceutical treatment of this condition. A 9-month-old infant treated with octreotide developed anicteric hepatitis with no other proven cause. After the discontinuation of this drug, the liver enzymes declined rapidly. Liver function tests should be followed in patients receiving octreotide.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23327817     DOI： 10.1515/jpem-2012-0372

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN： 0334-018X            Impact factor:   1.634


  9 in total

1.  Efficacy and safety of octreotide treatment for diazoxide-unresponsive congenital hyperinsulinism in China.

Authors:  Bingyan Cao; Wu Di; Chang Su; Jiajia Chen; Xuejun Liang; Min Liu; Wenjing Li; Xiaoqiao Li; Chunxiu Gong
Journal:  Pediatr Investig       Date:  2020-03-17

Review 2.  Congenital Hyperinsulinism: Diagnosis and Treatment Update.

Authors:  Hüseyin Demirbilek; Khalid Hussain
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-27

3.  Clinical practice guidelines for congenital hyperinsulinism.

Authors:  Tohru Yorifuji; Reiko Horikawa; Tomonobu Hasegawa; Masanori Adachi; Shun Soneda; Masanori Minagawa; Shinobu Ida; Takeo Yonekura; Yoshiaki Kinoshita; Yutaka Kanamori; Hiroaki Kitagawa; Masato Shinkai; Hideyuki Sasaki; Masaki Nio
Journal:  Clin Pediatr Endocrinol       Date:  2017-07-27

Review 4.  Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.

Authors:  Basma Haris; Saras Saraswathi; Khalid Hussain
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-02       Impact factor: 3.565

Review 5.  Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers.

Authors:  Alena Welters; Christian Lerch; Sebastian Kummer; Jan Marquard; Burak Salgin; Ertan Mayatepek; Thomas Meissner
Journal:  Orphanet J Rare Dis       Date:  2015-11-25       Impact factor: 4.123

Review 6.  Congenital hyperinsulinism: current status and future perspectives.

Authors:  Tohru Yorifuji
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-06-30

Review 7.  Diagnosis and treatment of hyperinsulinaemic hypoglycaemia and its implications for paediatric endocrinology.

Authors:  Huseyin Demirbilek; Sofia A Rahman; Gonul Gulal Buyukyilmaz; Khalid Hussain
Journal:  Int J Pediatr Endocrinol       Date:  2017-08-29

8.  Sirolimus-Induced Hepatitis in Two Patients with Hyperinsulinemic Hypoglycemia

Authors:  Belma Haliloğlu; Heybet Tüzün; Sarah E. Flanagan; Muhittin Çelik; Avni Kaya; Sian Ellard; Mehmet Nuri Özbek
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-08

9.  Possible New Strategies for the Treatment of Congenital Hyperinsulinism.

Authors:  Jelena Sikimic; Theresa Hoffmeister; Anne Gresch; Julia Kaiser; Winfried Barthlen; Carmen Wolke; Ilse Wieland; Uwe Lendeckel; Peter Krippeit-Drews; Martina Düfer; Gisela Drews
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-27       Impact factor: 5.555
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.